Reprogramming Cells With Synthetic Messenger RNA
OwnerLuigi WARRENinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerLuigi WARRENinventor
Estimating the term…
Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.
A method for accelerating cell lineage conversion comprising the steps of transfecting a cell with a composition comprising at least one synthetic mRNA encoding a engineered chimeric transcription factor incorporating a heterologous peptide sequence derived from the C-terminal transactivation domain (TAD) of Gal4, wherein the activity of said chimeric transcription factor is enhanced by the presence of said fused transactivation domain thereby promoting accelerated lineage conversion as compared to other methods of cell lineage conversion.
A method of cell therapy comprising:
Dependencies are inferred from the claim text.